Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities.
Ontology highlight
ABSTRACT: Metformin is a commonly prescribed type II diabetes medication that exhibits promising anticancer effects. Recently, these effects were found to be associated, at least in part, with a modulation of microRNA expression. However, the mechanisms by which single modulated microRNAs mediate the anticancer effects of metformin are not entirely clear and knowledge of such a process could be vital to maximize the potential therapeutic benefits of this safe and well-tolerated therapy. Our analysis here revealed that the expression of miR-21-5p was downregulated in multiple breast cancer cell lines treated with pharmacologically relevant doses of metformin. Interestingly, the inhibition of miR-21-5p following metformin treatment was also observed in mouse breast cancer xenografts and in sera from 9
SUBMITTER: Pulito C
PROVIDER: S-EPMC5501975 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
ACCESS DATA